

GLAXOSMITHKLINE PLC  
Form 6-K  
July 23, 2009

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending July 2009

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons**

I give below details of a change in the interests of Mr Jean Stéphane, a Person Discharging Managerial Responsibility, in the Ordinary Shares of the Company as a result of the following acquisition of shares:-

On 22 July 2009, Mr Jean Stéphane received the following award:-

| <b>Award under</b> | <b>Ordinary Shares</b> |
|--------------------|------------------------|
|--------------------|------------------------|

|                                       |       |
|---------------------------------------|-------|
| GlaxoSmithKline R&D Employee Inventor | 2,500 |
|---------------------------------------|-------|

Award Programme ("the Programme")

The Programme was established by the Company in December 2007 to reward those GlaxoSmithKline employee inventors who are named on the Company's product patents upon the first product launch of the relevant patent category in a major market.

Mr Stéphane, President and General Manager, GlaxoSmithKline Biologicals, is one of the inventors of Flu Pre-Pandemic (D-PAN) Vb61316.

The Ordinary shares subject to the award will be transferred to Mr Stéphane as soon as practicable. In accordance with the rules of the Programme, there will be no restrictions attached to the shares. The price of an Ordinary Share on the date of award was £11.53.

The Company and Mr Stéphane were advised of this transaction on 23 July 2009.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bicknell

Company Secretary

23 July 2009

**SIGNATURES**

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: July 23, 2009

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc